Silver carbene complexes: An emerging class of anticancer agents

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Silver carbene complexes : An emerging class of anticancer agents. / Kankala, Shravankumar; Thota, Niranjan; Björkling, Fredrik; Taylor, Myles K; Vadde, Ravinder; Balusu, Ramesh.

In: Drug Development Research, Vol. 80, No. 2, 03.2019, p. 188-199.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kankala, S, Thota, N, Björkling, F, Taylor, MK, Vadde, R & Balusu, R 2019, 'Silver carbene complexes: An emerging class of anticancer agents', Drug Development Research, vol. 80, no. 2, pp. 188-199. https://doi.org/10.1002/ddr.21478

APA

Kankala, S., Thota, N., Björkling, F., Taylor, M. K., Vadde, R., & Balusu, R. (2019). Silver carbene complexes: An emerging class of anticancer agents. Drug Development Research, 80(2), 188-199. https://doi.org/10.1002/ddr.21478

Vancouver

Kankala S, Thota N, Björkling F, Taylor MK, Vadde R, Balusu R. Silver carbene complexes: An emerging class of anticancer agents. Drug Development Research. 2019 Mar;80(2):188-199. https://doi.org/10.1002/ddr.21478

Author

Kankala, Shravankumar ; Thota, Niranjan ; Björkling, Fredrik ; Taylor, Myles K ; Vadde, Ravinder ; Balusu, Ramesh. / Silver carbene complexes : An emerging class of anticancer agents. In: Drug Development Research. 2019 ; Vol. 80, No. 2. pp. 188-199.

Bibtex

@article{b481752eef4d4603b3fbeb92bc72c8b3,
title = "Silver carbene complexes: An emerging class of anticancer agents",
abstract = "Hit, Lead & Candidate Discovery Cancer is a major global health problem with large therapeutic challenges. Although substantial progress has been made in cancer therapy, there still remains a need to develop novel and effective treatment strategies to treat several relapsed and refractory cancers. Recently, there has been growing demand for considering organometallics as antineoplastic agents. This review is focused on a group of organometallics, silver N-heterocyclic carbene complexes (SCCs) and their anticancer efficacy in targeting multiple pathways in various in vitro cancer model systems. However, the precise molecular mechanism of SCCs anticancer properties remains unclear. Here, we discuss the SCCs chemistry, potential molecular targets, possible molecular mechanism of action, and their application in cancer therapies.",
author = "Shravankumar Kankala and Niranjan Thota and Fredrik Bj{\"o}rkling and Taylor, {Myles K} and Ravinder Vadde and Ramesh Balusu",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = mar,
doi = "10.1002/ddr.21478",
language = "English",
volume = "80",
pages = "188--199",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "JohnWiley & Sons, Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Silver carbene complexes

T2 - An emerging class of anticancer agents

AU - Kankala, Shravankumar

AU - Thota, Niranjan

AU - Björkling, Fredrik

AU - Taylor, Myles K

AU - Vadde, Ravinder

AU - Balusu, Ramesh

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2019/3

Y1 - 2019/3

N2 - Hit, Lead & Candidate Discovery Cancer is a major global health problem with large therapeutic challenges. Although substantial progress has been made in cancer therapy, there still remains a need to develop novel and effective treatment strategies to treat several relapsed and refractory cancers. Recently, there has been growing demand for considering organometallics as antineoplastic agents. This review is focused on a group of organometallics, silver N-heterocyclic carbene complexes (SCCs) and their anticancer efficacy in targeting multiple pathways in various in vitro cancer model systems. However, the precise molecular mechanism of SCCs anticancer properties remains unclear. Here, we discuss the SCCs chemistry, potential molecular targets, possible molecular mechanism of action, and their application in cancer therapies.

AB - Hit, Lead & Candidate Discovery Cancer is a major global health problem with large therapeutic challenges. Although substantial progress has been made in cancer therapy, there still remains a need to develop novel and effective treatment strategies to treat several relapsed and refractory cancers. Recently, there has been growing demand for considering organometallics as antineoplastic agents. This review is focused on a group of organometallics, silver N-heterocyclic carbene complexes (SCCs) and their anticancer efficacy in targeting multiple pathways in various in vitro cancer model systems. However, the precise molecular mechanism of SCCs anticancer properties remains unclear. Here, we discuss the SCCs chemistry, potential molecular targets, possible molecular mechanism of action, and their application in cancer therapies.

U2 - 10.1002/ddr.21478

DO - 10.1002/ddr.21478

M3 - Journal article

C2 - 30387164

VL - 80

SP - 188

EP - 199

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 2

ER -

ID: 210979739